康柏西普与雷珠单抗对年龄相关性黄斑变性患者血清CRP、VEGF、眼压及视力的影响  

Effects of Conbercept and Ranibizumab on Serum Levels of CRP, VEGF,Intraocular Pressure and Visual Acuity in Patients with Age-Related Macular Degeneration

作　　者：魏艳丽[1] 冉莉君[1] 廖洪霞 陈少琼[1] 叶剑[1] WEI Yan-li;RAN Li-jun;LIAO Hong-xia;CHEN Shao-qiong;YE Jian(Department of Ophthalmology, Research Institute of Surgery, Daping Hospital of Third Military Medical University, Chongqing, 400032, Chin)

机构地区：[1]第三军医大学大坪医院野战外科研究所眼科,重庆400032

出　　处：《现代生物医学进展》2018年第8期1515-1518,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨康柏西普与雷珠单抗对年龄相关性黄斑变性(AMD)患者血清中C反应蛋白(CRP)、血管内皮生长因子(VEGF)水平、眼压(IOP)及视力的影响。方法:选取2015年4月到2016年5月在我院接受治疗的AMD患者70例作为研究对象,采用随机数字表法将所有患者分为观察组和对照组各35例,所有患者给予内眼手术标准玻璃体注射治疗,观察组给予康柏西普注射液1.5mg腔内注射,对照组给予雷珠单抗注射液0.5 mL腔内注射,对比两组患者治疗前、治疗后3d血清CRP、VEGF水平;记录并对比两组患者视力、IOP水平及并发症情况。结果:两组患者治疗后3d血清CRP、VEGF水平较治疗前下降,且观察组患者CRP、VEGF水平低于对照组(P<0.05);两组患者治疗后3d视力最小视角对数(logMAR)及IOP较治疗前降低,且观察组患者视力logMAR及IOP水平明显低于对照组,差异均有统计学意义(P<0.05)。治疗后3d,两组各出现1例玻璃体出血,并发症发生率比较差异无统计学意义(P>0.05)。结论:相对于雷珠单抗,康柏西普更能有效降低AMD患者血清CRP、VEGF水平和IOP,提高患者视力,改善病情,值得临床推广应用。Objective： To investigate the effects of conbercept and ranibizumab on serum levels of C reactive protein（CRP）,vascular endothelial growth factor（VEGF）, intraocular pressure（IOP） and visual acuity in patients with age-related macular degeneration（AMD）. Methods： A total of 70 patients with AMD, who were treated in Daping Hospital of Third Military Medical University from April 2015 to May 2016, were selected and randomly divided into observation group（n=35） and control group（n=35）. All patients were treated with standard vitreous injection for intra ocular surgery, the observation group was treated with 1.5 mg conbercept injection by intrapleural injection,and the control group was treated with 0.5 mL ranibizumab injection by intrapleural injection. The serum levels of CRP and VEGF of the two groups before treatment and 3d after treatment were compared, the visual acuity, data of IOP and complications were recorded and compared between the two groups. Results： The serum levels of CRP and VEGF in the two groups 3d after treatment were significantly lower than those before treatment, and the serum levels of CRP and VEGF in the observation group were significantly lower than those in the control group（P〈0.05）. The visual acuity minimum visual angle（logMAR） and IOP of the two groups 3d after treatment were lower than those before treatment, the visual acuity logMAR and IOP in the observation group were significantly lower than those in the control group, the difference was statistically significant（P〈0.05）. There was 1 case of vitreous hemorrhage in each group 3d after treatment, but there was no significant difference in the incidence of complications（P〈0.05）.Conclusion： Compared with ranibizumab, conbercept can effectively reduce the serum levels of CRP, VEGF and IOP in the patients with AMD,improve visual acuity and the patient＇s condition, which is worthy of clinical application.

关 键 词：康柏西普 雷珠单抗 年龄相关性黄斑变性 眼压 视力 

分 类 号：R774.5[医药卫生—眼科]